Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for John C. Rutherford
89.44
+2.08 (2.38%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 86.68 - 89.88
52 week 81.89 - 123.37
Open 88.66
Vol / Avg. 11.31M/14.45M
Mkt cap 131.97B
P/E 7.50
Div/yield 0.43/1.92
EPS 11.92
Shares 1.45B
Beta 1.04
Inst. own 82%
May 5, 2016
Gilead Sciences Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EDT - Add to calendar
Feb 10, 2016
Gilead Sciences Inc at Leerink Partners Global Healthcare Conference - Webcast
Feb 9, 2016
Gilead Sciences Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Feb 2, 2016
Q4 2015 Gilead Sciences Inc Earnings Call - Webcast
Feb 2, 2016
Q4 2015 Gilead Sciences Inc Earnings Release
Jan 11, 2016
Gilead Sciences Inc at JPMorgan Healthcare Conference
Dec 1, 2015
Gilead Sciences Inc at Piper Jaffray Healthcare Conference
Dec 1, 2015
Gilead Sciences Inc at Nasdaq OMX Investor Program - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 55.08% 55.47%
Operating margin 66.08% 68.00%
EBITD margin - 70.51%
Return on average assets 36.67% 41.86%
Return on average equity 102.84% 104.85%
Employees 7,000 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Brett Alan Pletcher Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Rutherford Carter Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
William A. Lee Ph.D. Executive Vice President - Research
Bio & Compensation  - Reuters